Pharmacology

Action Mechanism of Action Reference
AGONIST Erythropoietin receptor agonist PubMed FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Myocardial Infarction 3 D009203 ClinicalTrials
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Kidney Diseases 3 D007674 ClinicalTrials
Myocardial Infarction 3 D009203 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 3 D015451 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Dysgerminoma 2 D004407 ClinicalTrials
Brain Ischemia 2 D002545 ClinicalTrials
Brain Injuries 2 D001930 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Hematologic Neoplasms 2 D019337 ClinicalTrials
Acute Kidney Injury 2 D058186 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
19.87
Surgical and medical procedures
12.89
Vascular disorders
8.27
Injury, poisoning and procedural complications
7.62
Infections and infestations
6.99
Cardiac disorders
5.39
Respiratory, thoracic and mediastinal disorders
5.02
Gastrointestinal disorders
4.25
Investigations
4.08
Renal and urinary disorders
3.43
Nervous system disorders
3.2
Metabolism and nutrition disorders
2.94
Musculoskeletal and connective tissue disorders
2.75
Blood and lymphatic system disorders
2.62
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.53

Cross References

Resources Reference
CAS NUMBER 209810-58-2
ChEMBL CHEMBL1201566
FDA SRS 15UQ94PT4P